Literature DB >> 3874252

Phagocytosis and killing of common bacterial pathogens of the lung by human alveolar macrophages.

S Jonsson, D M Musher, A Chapman, A Goree, E C Lawrence.   

Abstract

To investigate factors that determine susceptibility of the lungs to infection with common respiratory pathogens, we studied phagocytosis and killing of nontypable Haemophilus influenzae, H. influenzae type b, Streptococcus pneumoniae types III, VI, and XIV, an unencapsulated variant of S. pneumoniae type III, and Staphylococcus aureus Cowan I, by using human alveolar macrophages obtained by bronchoalveolar lavage of healthy nonsmokers. After opsonization with 10% pooled human serum, mean uptake (+/- standard deviation) of nontypable H. influenzae (67.5% +/- 15.0%), unencapsulated S. pneumoniae type III (71.2% +/- 4.8%) and S. aureus (79.1% +/- 10.2%) was significantly greater (P less than .01) than that of H. influenzae type b (40.1% +/- 15.0%), and S. pneumoniae types III (4.4% +/- 3.1%), VI (11.8% +/- 9.6%), or XIV (8.7% +/- 7.0%). Nontypable H. influenzae was ingested after opsonization with much less pooled human serum than was H. influenzae type b, and uptake of encapsulated S. pneumoniae was not enhanced by as much as 80% pooled human serum. Intracellular killing of unencapsulated S. pneumoniae type III and nontypable H. influenzae was rapid and complete and corresponded to the degree of phagocytosis, but despite a high uptake, S. aureus were killed slowly and incompletely. The virulence of S. pneumoniae and H. influenzae as lung pathogens is thus determined jointly by encapsulation and the inadequate opsonizing effect of normal human serum, whereas that of S. aureus may be related to the organism's relative resistance to intracellular killing by alveolar macrophages.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3874252     DOI: 10.1093/infdis/152.1.4

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  31 in total

Review 1.  Streptococcus pneumoniae.

Authors:  J R Catterall
Journal:  Thorax       Date:  1999-10       Impact factor: 9.139

2.  Effect of concentrated ambient particles on macrophage phagocytosis and killing of Streptococcus pneumoniae.

Authors:  Hongwei Zhou; Lester Kobzik
Journal:  Am J Respir Cell Mol Biol       Date:  2006-11-01       Impact factor: 6.914

3.  Regulation of Apoptosis by Gram-Positive Bacteria: Mechanistic Diversity and Consequences for Immunity.

Authors:  Glen C Ulett; Elisabeth E Adderson
Journal:  Curr Immunol Rev       Date:  2006-05

Review 4.  Secondary bacterial infections in influenza virus infection pathogenesis.

Authors:  Amber M Smith; Jonathan A McCullers
Journal:  Curr Top Microbiol Immunol       Date:  2014       Impact factor: 4.291

5.  Mathematical analysis of cell-target encounter rates in two dimensions. The effect of chemotaxis.

Authors:  E S Fisher; D A Lauffenburger
Journal:  Biophys J       Date:  1987-05       Impact factor: 4.033

6.  17(R)-Resolvin D1 differentially regulates TLR4-mediated responses of primary human macrophages to purified LPS and live E. coli.

Authors:  Christine D Palmer; Christy J Mancuso; Jerrold P Weiss; Charles N Serhan; Eva C Guinan; Ofer Levy
Journal:  J Leukoc Biol       Date:  2011-06-07       Impact factor: 4.962

Review 7.  Pneumococcal Vaccination Strategies. An Update and Perspective.

Authors:  Andrew C Berical; Drew Harris; Charles S Dela Cruz; Jennifer D Possick
Journal:  Ann Am Thorac Soc       Date:  2016-06

Review 8.  Alcohol abuse and Streptococcus pneumoniae infections: consideration of virulence factors and impaired immune responses.

Authors:  Minny Bhatty; Stephen B Pruett; Edwin Swiatlo; Bindu Nanduri
Journal:  Alcohol       Date:  2011-09       Impact factor: 2.405

9.  Intracellular trafficking and killing of Streptococcus pneumoniae by human alveolar macrophages are influenced by opsonins.

Authors:  S B Gordon; G R Irving; R A Lawson; M E Lee; R C Read
Journal:  Infect Immun       Date:  2000-04       Impact factor: 3.441

10.  Inhaled delivery of 23-valent pneumococcal polysaccharide vaccine does not result in enhanced pulmonary mucosal immunoglobulin responses.

Authors:  Stephen B Gordon; Rose Malamba; Neema Mthunthama; Elizabeth R Jarman; Kondwani Jambo; Khuzwayo Jere; Eduard E Zijlstra; Malcolm E Molyneux; John Dennis; Neil French
Journal:  Vaccine       Date:  2008-08-15       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.